Anti-vascular endothelial growth factor receptor in colorectal cancer: A review

키워드

참고문헌 (62)

1. Ortega J, "Current progress in targeted therapy for colorectal cancer", Cancer Control, 17, pp.7~15 (2010)
2. Jemal A, "Cancer statistics, 2008", CA Cancer J Clin, 58, pp.71~96 (2008)
3. Hurwitz H, "Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer", N Engl J Med, 350, pp.2335~2342 (2004)
4. Karamysheva AF, "Mechanisms of angiogenesis", Biochemistry(Mosc), 73, pp.751~762 (2008)
5. Döme B, "Alternative vascularization mechanisms in cancer : pathology and therapeutic implications", Am J Pathol, 170, pp.1~15 (2007)
6. Folkman J, "Is angiogenesis an organizing principle in biology and medicine?", J Pediatr Surg, 42, pp.1~11 (2007)
7. Van Cutsem E, "O-0024 Intravenous(IV)aflibercept versus placebo in combination with irinotecan", 5-FU(FOLFIRI)for secondline treatment of metastatic colorectal cancer(MCRC) : results of a multinational phase III trial(EFC10262-VELOUR), 2011, pp.22(Suppl 5), v18~
8. Folkman J, "Seminars in medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis", N Engl J Med, 333, pp.1757~1763 (1995)
9. Zetter BR, "Angiogenesis and tumor metastasis", Annu Rev Med, 49, pp.407~424 (1998)
10. Bergers G, "Tumorigenesis and the angiogenic switch", Nat Rev Cancer, 3, pp.401~410 (2003)
11. Hicklin DJ, "Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis", J Clin Oncol, 23, pp.1011~1027 (2005)
12. Ferrara N., "Vascular endothelial growth factor as a target for anticancer therapy", Oncologist, 9(Suppl 1), pp.2~10 (2004)
13. Ferrara N, "Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer", Nat Rev Drug Discov, 3, pp.391~400 (2004)
14. Carrato A, "Anti-VEGF therapy : a new approach to colorectal cancer therapy", Expert Rev Anticancer Ther, 6, pp.1385~1396 (2006)
15. Ishigami SI, "Predictive value of vascular endothelial growth factor(VEGF)in metastasis and prognosis of human colorectal cancer", Br J Cancer, 78, pp.1379~1384 (1998)
16. Wong MP, "Vascular endothelial growth factor is up-regulated in the early pre-malignant stage of colorectal tumour progression", Int J Cancer, 81, pp.845~850 (1999)
17. Martins SF, "Role of endoglin and VEGF family expression in colorectal cancer prognosis and anti-angiogenic therapies", World J Clin Oncol, 2, pp.272~280 (2011)
18. Jain RK, "Normalization of tumor vasculature : an emerging concept in antiangiogenic therapy", Science, 307, pp.58~62 (2005)
19. Kerbel RS, "Antiangiogenic therapy : a universal chemosensitization strategy for cancer?", Science, 312, pp.1171~1175 (2006)
20. Shaked Y, "Rapid chemotherapy-induced acute endothelial progenitor cell mobilization : implications for antiangiogenic drugs as chemosensitizing agents", Cancer Cell, 14, pp.263~273 (2008)
21. Gordon MS, "Phase I safety and pharmacokinetic study of recombinant human antivascular endothelial growth factor in patients with advanced cancer", J Clin Oncol, 19, pp.843~850 (2001)
22. Scheithauer W, "Bevacizumab plus oxaliplatin-based regimens for the treatment of colorectal cancer", Onkologie, 32, pp.431~439 (2009)
23. Fuchs CS, "Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer : results from the BICC-C Study", J Clin Oncol, 25, pp.4779~4786 (2007)
24. Fuchs CS, "Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer : updated results from the BICC-C study", J Clin Oncol, 26, pp.689~690 (2008)
25. Saltz LB, "Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer : a randomized phase III study", J Clin Oncol, 26, pp.2013~2019 (2008)
26. Giantonio BJ, "Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200", J Clin Oncol, 25, pp.1539~1544 (2007)
27. Kabbinavar FF, "Combined analysis of efficacy : the addition of bevacizumab to fluorouracil", leucovorin improves survival for patients with metastatic colorectal cancer, 2005, pp.23, 3706~3712
28. Hurwitz H, "Bevacizumab combined with standard fluoropyrimidinebased chemotherapy regimens to treat colorectal cancer", Oncology, 69(Suppl 3), pp.17~24 (2005)
29. Chu E, "An update on the current and emerging targeted agents in metastatic colorectal cancer", Clin Colorectal Cancer, 11, pp.1~13 (2012)
30. Kozloff M, "Clinical outcomes associated with bevacizumabcontaining treatment of metastatic colorectal cancer: the BRiTE observational cohort study", Oncologist, 14, pp.862~870 (2009)
31. Bennouna J, "Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial", Lancet Oncol, 14, pp.29~37 (2013)
32. Shaheen RM, "Inhibited growth of colon cancer carcinomatosis by antibodies to vascular endothelial and epidermal growth factor receptors", Br J Cancer, 85, pp.584~589 (2001)
33. Ellis LM, "Epidermal growth factor receptor in tumor angiogenesis", Hematol Oncol Clin North Am, 18, pp.1007~1021 (2004)
34. Hecht JR, "A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer", J Clin Oncol, 27, pp.672~680 (2009)
35. Tol J, "Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer", N Engl J Med, 363, pp.563~572 (2010)
36. Saltz L, "Phase III trial of cetuximab, bevacizumab, and 5-fluorouracil", leucovorin vs. FOLFOXbevacizumab in colorectal cancer, 2012, pp.11, 101~111
37. De Gramont A, "AVANT: results from a randomized, three-arm multinational phase III study to investigate bevacizumab with either XELOX or FOLFOX4 versus FOLFOX4alone as adjuvant treatment for colon cancer", J Clin Oncol, 29(4 Suppl), pp.362~ (2011)
38. Wolmark N, "A phase III trial comparing mFOLFOX6 to mFOLFOX6 plus bevacizumab in stage II or III carcinoma of the colon: results of NSABP protocol C-08", J Clin Oncol, 27(18 Suppl), pp.LBA4~ (2009)
39. Holash J, "VEGFTrap : a VEGF blocker with potent antitumor effects", Proc Natl Acad Sci U S A, 99, pp.11393~11398 (2002)
40. Stewart MW, "Aflibercept(VEGF-TRAP) : the next anti-VEGF drug", Inflamm Allergy Drug Targets, 10, pp.497~508 (2011)
41. Cursiefen C, "VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment", J Clin Invest, 113, pp.1040~1050 (2004)
42. Kim ES, "Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma", Proc Natl Acad Sci U S A, 99, pp.11399~11404 (2002)
43. Teng LS, "Clinical applications of VEGFtrap(aflibercept)in cancer treatment", J Chin Med Assoc, 73, pp.449~456 (2010)
44. Lal D, "Aflibercept exerts antivascular effects and enhances levels of anthracycline chemotherapy in vivo in human acute myeloid leukemia models", Mol Cancer Ther, 9, pp.2737~2751 (2010)
45. Hu L, "Vascular endothelial growth factor trap combined with paclitaxel strikingly inhibits tumor and ascites, prolonging survival in a human ovarian cancer model", Clin Cancer Res, 11(19 Pt 1), pp.6966~6971 (2005)
46. Lockhart AC, "Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors", J Clin Oncol, 28, pp.207~214 (2010)
47. Tew WP, "Phase 1study of aflibercept administered subcutaneously to patients with advanced solid tumors", Clin Cancer Res, 16, pp.358~366 (2010)
48. de Groot JF, "Phase II study of aflibercept in recurrent malignant glioma : a North American Brain Tumor Consortium study", J Clin Oncol, 29, pp.2689~2695 (2011)
49. Jin K, "Aflibercept(VEGF Trap) : one more double-edged sword of anti-VEGF therapy for cancer?", Clin Transl Oncol, 12, pp.526~532 (2010)
50. Rudge JS, "VEGF trap complex formation measures production rates of VEGF, providing a biomarker for predicting efficacious angiogenic blockade", Proc Natl Acad Sci U S A, 104, pp.18363~18370 (2007)
51. Reichert JM, "Antibody-based therapeutics to watch in 2011", MAbs, 3, pp.76~99 (2011)
52. "Two year results of phase 3 studies with EYLEATM (aflibercept) injection in wet AMD show sustained improvement in visual acuity" (2011)[URL]
53. Tabernero J, "Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study", Lancet Oncol, 16, pp.499~508 (2015)
54. Grothey A, "Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer : results from a large observational cohort study(BRiTE)", J Clin Oncol, 26, pp.5326~5334 (2008)
55. Mass RD, "Clinical benefit from bevacizumab(BV)in responding(R)and non-responding(NR)patients(pts)with metastatic colorectal cancer(mCRC)", J Clin Oncol, 23(16 Suppl), pp.3514~ (2005)
56. Kopetz S, "Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer : efficacy and circulating angiogenic biomarkers associated with therapeutic resistance", J Clin Oncol, 28, pp.453~459 (2010)
57. "Combination chemotherapy and bevacizumab with or without erlotinib in treating patients with metastatic colorectal cancer that cannot be removed by surgery" (2005)[URL]
58. Chaplin DJ, "Current development status of smallmolecule vascular disrupting agents", Curr Opin Investig Drugs, 7, pp.522~528 (2006)
59. Kerbel RS, "The anti-angiogenic basis of metronomic chemotherapy", Nat Rev Cancer, 4, pp.423~436 (2004)
60. Pohl M, "Biomarkers of anti-angiogenic therapy in metastatic colorectal cancer(mCRC) : original data and review of the literature", Z Gastroenterol, 49, pp.1398~1406 (2011)
61. Loupakis F, "Targeting vascular endothelial growth factor pathway in first-line treatment of metastatic colorectal cancer : state-of-the-art and future perspectives in clinical and molecular selection of patients", Curr Cancer Drug Targets, 10, pp.37~45 (2010)
62. Matsusaka S, "Circulating endothelial cells predict for response to bevacizumab-based chemotherapy in metastatic colorectal cancer", Cancer Chemother Pharmacol, 68, pp.763~768 (2011)

관련 논문AI추천